Results: Of the 519 enrolled pts, 504 (with complete data on the FiRST questionnaire) were analyzed at M3. A positive screening for comorbid FM was found in 192 pts (38%) at M0 and in 127 (25%) pts at M3. Correlation between FiRST at M0 and M3 was weak with a Kappa coefficient correlation of 0.4 [0,3 -0,5 Background: Fibromyalgia (FM) can be a comorbid condition in axial spondyloarthritis (axSpA). FM screening questionnaires and classification criteria fulfillment may demonstrate different prevalence and patients' characteristics may differ. Objectives: To evaluate frequency of comorbid FM, and the differences between axSpA patients with/without comorbid FM according to screening (FiRST) and classification tools (ACR1990 FM criteria). Methods: A multicenter national study involving 39 rheumatology centers in France included 519 patients with axSpA starting an anti-TNF treatment (PredictSpA study; ClinicalTrials.gov: NCT03039088). Patients (pts) were screened for FM with the FiRST questionnaire and classified as FM by ACR 1990 criteria. Demographic characteristics, comorbidities, axSpA characteristics, CRP and imaging were recorded in all patients. Kappa coefficient (and its 95% CI) was calculated to compare FiRST and ACR1990 criteria. Baseline characteristics associated with FM were evaluated by univariable and multivariable logistic regression (including the variables with a p value<0.20 in the univariable analysis). Results: In the 519 pts (females: 46%, age: 42±12 years, mean BASDAI 5.7±2.0, mean ASDAS-CRP 3.3±0.9), a comorbid FM was screened in 38% and diagnosed in 16% of pts. Agreement between FiRST and ACR1990 was poor, with a Kappa coefficient of 0.2 [0.2-0.3]. In the multivariable analysis, comorbid FM (by the FiRST questionnaire) in axSpA
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In the multivariable analysis, comorbid FM (by the FiRST questionnaire) in axSpA Background: Auto-antibodies to the RNA binding protein Ro60 are present in patients with autoimmune disorders such as systemic lupus erythematosus (SLE). In addition to its established role as an auto-antigen, Ro60 has been found to bind Alu RNA retroelements whereby it may target Alu retroelement RNA for degradation suggesting a novel putative function of this auto-antigen. If Ro60 modulates the amount of cellular RNA then one may hypothesise an association with toll-like receptor (TLR) 7 stimulation threshold. Objectives: To measure the physiological levels of intracellular Ro60 protein in healthy children and adolescents and investigate a possible link between Ro60 protein expression and interferon-α (IFN-α) production after TLR7 stimulation. Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from blood from 48 healthy children and adolescents (age range 6.7-17.9 years old). Cell lysates from thawed PBMC samples were tested for Ro60 expression by Western blot. PBMCs were also stimulated for 20 hours with TLR7/8 agonist R848, at 1ug/ml in the presence of brefeldin A, and plasmacytoid dendritic cell (pDC) IFN-α expression was measured using flow cytometry. Statistical tests to measure correlation between IFN-α expression in (pDCs) and PBMC Ro60 expression were performed using SPSS. Results: Ro60 expression in PBMCs correlated negatively with age (Spearman's rho = -0.317, p=0.032). When participants were divided into two groups based on their self-reported puberty status, Ro60 expression was higher in the pre-pubertal group (p=0.02). There was, however, no difference in Ro60 expression between males and females (p=0.44) or when sexes were stratified according to pubertal status. pDC IFN-α production after TLR 7 stimulation, did not correlate with ex vivo PBMC Ro60 expression overall (Spearman's rho =0.159, p=0.302) however a moderate positive correlation was observed in pre-pubertal samples only (Spearman's rho =0.554, p=0.021). Conclusions: Ro60 expression decreases with age in healthy young people. These findings need to be confirmed in a larger cohort and further studies are necessary to investigate the link between Ro60 expression and TLR7 signalling across different age groups as well as in patients with SLE. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.5073
